Not medical advice. A record of published research and our assessments of it. The limits

Trials

Registered trials that could change what is known. Status and completion dates are read from ClinicalTrials.gov and every change is kept, including dates that slip.

01Enrolls people without diabetes

152 trials

Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie DietNCT04122716 · Unknown · Phase 4 · 215 participants · Primary completion 2019-11 · BMI 32 or higher
Evaluating Liraglutide in Alzheimer's DiseaseNCT01843075 · Unknown · Phase 2 · 204 participants · Primary completion 2019-12
Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS PatientsNCT04029272 · Unknown · Phase 4 · 80 participants · Primary completion 2020-02-28 · BMI 25 or higher
non-weight indication: endocrine, other_emerging
Effects of Liraglutide in Chronic Obstructive Pulmonary DiseaseNCT03466021 · Completed · Phase 4 · 40 participants · Primary completion 2020-05-31 · BMI 27 or higher
population of special interest (non-obese / healthy / non-diabetic)
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOSNCT03480022 · Completed · Results posted · Phase 3 · 88 participants · Primary completion 2021-02-22 · BMI 27 or higher
non-weight indication: endocrine, other_emerging
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's DiseaseNCT03439943 · Completed · Phase 2 · 156 participants · Primary completion 2021-04-15
non-weight indication: parkinsons
SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's DiseaseNCT04269642 · Unknown · Phase 2 · 99 participants · Primary completion 2021-09-29
non-weight indication: parkinsons
Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male VolunteersNCT03835013 · Completed · NA · 26 participants · Primary completion 2021-11-01 · BMI 18 or higher
non-weight indication: cardiovascular
Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep ApneaNCT04186494 · Completed · NA · 30 participants · Primary completion 2021-12-31
non-weight indication: sleep
Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.NCT04969627 · Completed · Phase 4 · 60 participants · Primary completion 2022-01-04 · BMI 24 or higher
non-weight indication: endocrine, other_emerging
Daily Liraglutide for Nicotine DependenceNCT03712098 · Completed · Results posted · Phase 2 · 40 participants · Primary completion 2022-05-25
non-weight indication: addiction
Study of the Cardiometabolic Effects of Obesity PharmacotherapyNCT04575194 · Unknown · Phase 4 · 40 participants · Primary completion 2022-09-30 · BMI 27 or higher
non-weight indication: cardiovascular
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)NCT04944992 · Completed · Results posted · Phase 2 · 145 participants · Primary completion 2022-10-19 · BMI 25 or higher
non-weight indication: liver, addiction
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)NCT04216589 · Completed · Results posted · Phase 2 · 51 participants · Primary completion 2023-03-16
non-weight indication: cardiovascular, liver, immune, addiction
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityNCT03574597 · Completed · Results posted · Phase 3 · 17604 participants · Primary completion 2023-06-21
non-weight indication: cardiovascular, cerebrovascular
Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic NephropathyNCT06182891 · Completed · NA · 300 participants · Primary completion 2023-06-30
non-weight indication: kidney
Use of a GLP-1R Agonist to Treat Opioid Use DisorderNCT04199728 · Completed · Results posted · Phase 1, Phase 2 · 27 participants · Primary completion 2023-09-13
non-weight indication: addiction, ophthalmologic
Treating PCOS With Semaglutide vs Active Lifestyle InterventionNCT03919929 · Completed · Results posted · Phase 2, Phase 3 · 60 participants · Primary completion 2023-10-03
non-weight indication: liver, endocrine
Exenatide Treatment in Parkinson's DiseaseNCT04305002 · Unknown · Phase 2 · 60 participants · Primary completion 2023-10-10
non-weight indication: parkinsons
Semaglutide Use in Elderly Obese PatientsNCT05302596 · Completed · Results posted · Phase 2 · 16 participants · Primary completion 2023-10-23 · BMI 30 or higher
non-weight indication: lean_mass, aging
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)NCT04166773 · Completed · Results posted · Phase 2 · 190 participants · Primary completion 2023-12-11 · BMI 27 or higher
non-weight indication: liver, addiction
Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF PatientsNCT04885634 · Withdrawn · Phase 3 · Primary completion 2024-01 · BMI 30 or higher
non-weight indication: cardiovascular
Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's DiseaseNCT04232969 · Completed · Phase 3 · 194 participants · Primary completion 2024-02-24
non-weight indication: parkinsons
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep ApneaNCT05412004 · Completed · Results posted · Phase 3 · 469 participants · Primary completion 2024-03-12 · BMI 30 or higher
non-weight indication: sleep
Semaglutide for Alcohol Use DisorderNCT05520775 · Completed · Results posted · Phase 2 · 48 participants · Primary completion 2024-04-12
non-weight indication: addiction
Effects of Semaglutide in HIV-Associated LipohypertrophyNCT04019197 · Active not recruiting · Results posted · Phase 2 · 108 participants · Primary completion 2024-04-30
non-weight indication: other_emerging
Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney DiseaseNCT05254418 · Completed · Results posted · Phase 2 · 7 participants · Primary completion 2024-05-01
non-weight indication: kidney, muscle
Effects of Semaglutide on Nicotine IntakeNCT05530577 · Completed · Results posted · Phase 2 · 24 participants · Primary completion 2024-05-13
non-weight indication: addiction
SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without DiabetesNCT04889183 · Completed · Phase 3 · 125 participants · Primary completion 2024-05-28
non-weight indication: kidney
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT TrialNCT04847557 · Completed · Results posted · Phase 3 · 731 participants · Primary completion 2024-07-02 · BMI 30 or higher
non-weight indication: cardiovascular
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)NCT04971785 · Completed · Results posted · Phase 2 · 457 participants · Primary completion 2024-11-12 · BMI 23 or higher
non-weight indication: liver, addiction
Effect Of Semaglutide In Coronary Atheroma PlaqueNCT05071417 · Unknown · Phase 3 · 120 participants · Primary completion 2024-12
non-weight indication: cardiovascular
Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension TreatmentNCT06361823 · Unknown · Phase 3 · 74 participants · Primary completion 2024-12-01
non-weight indication: cardiovascular, other_emerging
GLP1R in Parkinson's DiseaseNCT03659682 · Unknown · Phase 2 · 120 participants · Primary completion 2024-12-31
non-weight indication: inflammation, parkinsons, neuroinflammation
Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary SyndromeNCT05702905 · Unknown · Phase 4 · 75 participants · Primary completion 2024-12-31 · BMI 28 or higher
non-weight indication: endocrine, other_emerging
The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial PressureNCT06027567 · Completed · Phase 4 · 38 participants · Primary completion 2025-01-28 · BMI 27 or higher
non-weight indication: cardiovascular, cancer, other_emerging
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or ObeseNCT06445075 · Completed · Phase 2 · 102 participants · Primary completion 2025-03-04
LIROH - Liraglutide for Obesity in HIVNCT06438146 · Unknown · Phase 4 · 40 participants · Primary completion 2025-05 · BMI 30 or higher
non-weight indication: immune, other_emerging
Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 DrugsNCT07303556 · Active not recruiting · NA · 120 participants · Primary completion 2025-07-01 · BMI 25 or higher
non-weight indication: cardiovascular
Mechanisms of Semaglutide Therapy in Heart Failure PatientsNCT06541509 · Unknown · Phase 1, Phase 2 · 10 participants · Primary completion 2025-07-10
non-weight indication: inflammation, cardiovascular, cancer
Semaglutide Therapy for Alcohol Reduction - TulsaNCT05891587 · Completed · Phase 2 · 80 participants · Primary completion 2025-07-30
non-weight indication: addiction
Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?NCT05895643 · Completed · Phase 2 · 108 participants · Primary completion 2025-07-31
non-weight indication: addiction
Acute Subcutaneous SemaglutidE in Acute Ischemic sTrokeNCT05630586 · Recruiting · Phase 2 · 380 participants · Primary completion 2025-09
non-weight indication: cerebrovascular
Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney DiseaseNCT06344247 · Unknown · NA · 48 participants · Primary completion 2025-09-01 · BMI 85 or higher
non-weight indication: kidney
Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)NCT05646199 · Unknown · Phase 2, Phase 3 · 60 participants · Primary completion 2025-09-30
non-weight indication: endocrine, other_emerging
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151 · Completed · Phase 2 · 146 participants · Primary completion 2025-10-01 · BMI 27 or higher
non-weight indication: kidney
Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)NCT05892432 · Completed · Phase 2 · 50 participants · Primary completion 2025-11-04 · BMI 25 or higher
non-weight indication: addiction, ophthalmologic
Exenatide for Smoking Cessation and Prevention of Weight GainNCT05610800 · Completed · Phase 2 · 140 participants · Primary completion 2025-11-07
non-weight indication: addiction
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367 · Completed · Phase 3 · 445 participants · Primary completion 2025-11-14 · BMI 27 or higher
non-weight indication: osteoarthritis
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or OverweightNCT06588296 · Completed · Phase 3 · 279 participants · Primary completion 2025-11-18 · BMI 27 or higher
non-weight indication: rheumatologic
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)NCT05877547 · Completed · Phase 2 · 381 participants · Primary completion 2025-12-29
non-weight indication: liver, addiction
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and InfertilityNCT05952882 · Unknown · Phase 3 · 188 participants · Primary completion 2025-12-31 · BMI 27 or higher
non-weight indication: endocrine, other_emerging
Efficacy of Mazdutide for Treating PCOSNCT06519656 · Recruiting · Phase 1, Phase 2 · 50 participants · Primary completion 2025-12-31 · BMI 28 or higher
non-weight indication: endocrine, other_emerging
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightNCT06588283 · Completed · Phase 3 · 281 participants · Primary completion 2026-01-08 · BMI 27 or higher
non-weight indication: rheumatologic
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066 · Completed · Phase 3 · 2335 participants · Primary completion 2026-04-06 · BMI 30 or higher
non-weight indication: osteoarthritis, sleep
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045 · Completed · Phase 3 · 1946 participants · Primary completion 2026-04-16 · BMI 35 or higher
non-weight indication: cardiovascular
Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart ValvesNCT07610174 · Completed · Phase 2 · 160 participants · Primary completion 2026-04-29
non-weight indication: cardiovascular
Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)NCT06764056 · Not yet recruiting · NA · 120 participants · Primary completion 2026-05
non-weight indication: liver, nutrition
DUTCH Weight Control in Atrial Fibrillation StudyNCT06184633 · Recruiting · Phase 4 · 280 participants · Primary completion 2026-05-01 · BMI 30 or higher
non-weight indication: cardiovascular
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · Completed · Phase 3 · 5531 participants · Primary completion 2026-06-01 · BMI 27 or higher
non-weight indication: cardiovascular, cerebrovascular, kidney
Semaglutide for Post-Smoking Cessation Weight ManagementNCT06173778 · Recruiting · Phase 2 · 197 participants · Primary completion 2026-07-01 · BMI 27 or higher
non-weight indication: addiction
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05536804 · Completed · Phase 2 · 134 participants · Primary completion 2026-07-06 · BMI 27 or higher
non-weight indication: kidney
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection FractionNCT05371496 · Completed · Phase 4 · 81 participants · Primary completion 2026-07-17 · BMI 30 or higher
non-weight indication: cardiovascular
Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation TherapyNCT06908694 · Recruiting · Phase 4 · 20 participants · Primary completion 2026-07-31
non-weight indication: cardiovascular, cancer
Effect of Semaglutide in Patients With Psoriasis and ObesityNCT06937060 · Recruiting · Phase 3 · 14 participants · Primary completion 2026-07-31
non-weight indication: rheumatologic
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver TransplantNCT05424003 · Recruiting · Phase 2 · 50 participants · Primary completion 2026-08-01
non-weight indication: liver
Tirzepatide for Alcohol Use DisorderNCT06994338 · Recruiting · Phase 2 · 42 participants · Primary completion 2026-08-31
non-weight indication: addiction
Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)NCT05254314 · Active not recruiting · Phase 2 · 100 participants · Primary completion 2026-09 · BMI 27 or higher
non-weight indication: other_emerging
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityNCT06862908 · Recruiting · Phase 2 · 141 participants · Primary completion 2026-09-24 · BMI 28 or higher
non-weight indication: cardiovascular
Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2NCT06396416 · Recruiting · Phase 4 · 60 participants · Primary completion 2026-09-30
non-weight indication: kidney
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045 · Active not recruiting · Phase 3 · 600 participants · Primary completion 2026-11 · BMI 27 or higher
non-weight indication: sleep
Semaglutide in Auto-HSCTNCT06449625 · Not yet recruiting · Phase 2 · 40 participants · Primary completion 2026-12-31 · BMI 18 or higher
non-weight indication: inflammation
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal WomenNCT07057310 · Enrolling by invitation · Phase 4 · 30 participants · Primary completion 2026-12-31 · BMI 30 or higher
non-weight indication: aging
TIRzepatide for the Treatment of Obesity in Patients With Atrial FibrillationNCT06802081 · Recruiting · Phase 2 · 100 participants · Primary completion 2026-12-31 · BMI 27 or higher
non-weight indication: cardiovascular
Liraglutide Effect in Atrial FibrillationNCT03856632 · Active not recruiting · Phase 4 · 60 participants · Primary completion 2026-12-31 · BMI 27 or higher
non-weight indication: cardiovascular
Sit Less, Interact and Move More (SLIMM) 2 StudyNCT05173714 · Recruiting · Phase 2 · 156 participants · Primary completion 2026-12-31
non-weight indication: kidney
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）NCT06884293 · Active not recruiting · Phase 3 · 479 participants · Primary completion 2026-12-31 · BMI 27 or higher
non-weight indication: liver
A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young AdultsNCT07364175 · Recruiting · NA · 60 participants · Primary completion 2027-01 · BMI 27 or higher
non-weight indication: cardiovascular
Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT StudyNCT07509112 · Not yet recruiting · Phase 2 · 40 participants · Primary completion 2027-01
population of special interest (non-obese / healthy / non-diabetic)
GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic ArthritisNCT07251556 · Not yet recruiting · Phase 4 · 40 participants · Primary completion 2027-01-01 · BMI 25 or higher
non-weight indication: cardiovascular, rheumatologic
Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in PsoriasisNCT07401992 · Recruiting · Phase 4 · 62 participants · Primary completion 2027-02-28 · BMI 25 or higher
non-weight indication: inflammation, rheumatologic
Study of Tirzepatide for Recovery and Alcohol Use ManagementNCT06727331 · Recruiting · Phase 2 · 20 participants · Primary completion 2027-03-01
non-weight indication: addiction
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) PatientsNCT06774079 · Recruiting · Phase 4 · 24 participants · Primary completion 2027-03-05 · BMI 27 or higher
non-weight indication: inflammation, rheumatologic
The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery DiseaseNCT06606821 · Recruiting · Phase 4 · 124 participants · Primary completion 2027-03-20
non-weight indication: cardiovascular
Semaglutide Therapy for Alcohol Reduction (STAR)NCT06015893 · Active not recruiting · Phase 2 · 63 participants · Primary completion 2027-03-31
non-weight indication: addiction
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot StudiesNCT07483801 · Not yet recruiting · Phase 4 · 112 participants · Primary completion 2027-04 · BMI 30 or higher
non-weight indication: cardiovascular
Effects of Tirzepatide on Muscle and Vascular Health in Obese Older AdultsNCT06811324 · Recruiting · Phase 2 · 20 participants · Primary completion 2027-04-01 · BMI 30 or higher
non-weight indication: cardiovascular, muscle
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With ObesityNCT07293325 · Recruiting · NA · 66 participants · Primary completion 2027-04-02 · BMI 30 or higher
non-weight indication: aging
A Study of CS060380 Tablets in Patients With MASH and ObesityNCT07466017 · Active not recruiting · Phase 2 · 130 participants · Primary completion 2027-04-30 · BMI 30 or higher
non-weight indication: liver
GLP-1R Agonist Treatment for Opioid Use DisorderNCT06548490 · Recruiting · Phase 2 · 200 participants · Primary completion 2027-04-30 · BMI 18 or higher
non-weight indication: addiction
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)NCT05356104 · Recruiting · Phase 2 · 110 participants · Primary completion 2027-05
population of special interest (non-obese / healthy / non-diabetic)
Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)NCT06191848 · Recruiting · Phase 4 · 352 participants · Primary completion 2027-05
non-weight indication: osteoarthritis
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2NCT06931028 · Recruiting · Phase 3 · 260 participants · Primary completion 2027-05-07 · BMI 28 or higher
non-weight indication: sleep
Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)NCT07292519 · Not yet recruiting · Phase 2 · 46 participants · Primary completion 2027-05-15 · BMI 27 or higher
non-weight indication: cognition, addiction
Efficacy of a GLP-1/FGF21 Dual Agonist for Treating PCOSNCT07616037 · Recruiting · Phase 2 · 30 participants · Primary completion 2027-06
non-weight indication: endocrine, other_emerging
Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart DiseaseNCT07354880 · Not yet recruiting · Phase 4 · 30 participants · Primary completion 2027-06-30
non-weight indication: cardiovascular
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 SemaglutideNCT07040592 · Recruiting · Phase 2 · 30 participants · Primary completion 2027-06-30
non-weight indication: addiction, other_emerging
Tirzepatide in MetALDNCT07046819 · Recruiting · Phase 2 · 120 participants · Primary completion 2027-07-30 · BMI 25 or higher
non-weight indication: addiction
Tirzepatide in Idiopathic Intracranial Hypertension TrialNCT07191873 · Recruiting · Phase 4 · 60 participants · Primary completion 2027-08 · BMI 30 or higher
non-weight indication: cardiovascular, other_emerging
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422 · Active not recruiting · Phase 3 · 974 participants · Primary completion 2027-09 · BMI 25 or higher
non-weight indication: cardiovascular
Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)NCT07756359 · Not yet recruiting · Phase 4 · 20 participants · Primary completion 2027-09
non-weight indication: inflammation
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)NCT03884075 · Recruiting · Phase 2 · 104 participants · Primary completion 2027-09-03
non-weight indication: liver, addiction
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use DisorderNCT06651177 · Recruiting · Phase 2 · 310 participants · Primary completion 2027-09-30
non-weight indication: addiction
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast CancerNCT06518837 · Recruiting · Phase 2 · 40 participants · Primary completion 2027-09-30
non-weight indication: cancer
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)NCT06864026 · Recruiting · Phase 4 · 200 participants · Primary completion 2027-11
non-weight indication: rheumatologic
Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese IndividualsNCT07609160 · Not yet recruiting · NA · 108 participants · Primary completion 2027-11-30 · BMI 27 or higher
non-weight indication: muscle
Albuminuria Reduction Study With Survodutide Treatment in Kidney DiseaseNCT07206290 · Not yet recruiting · Phase 2 · 120 participants · Primary completion 2027-11-30 · BMI 21 or higher
non-weight indication: kidney
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial FibrillationNCT06499857 · Recruiting · Phase 3 · 200 participants · Primary completion 2027-12
non-weight indication: cardiovascular
COMMETS- Combination MCI Metabolic SyndromeNCT06072963 · Recruiting · Phase 2 · 80 participants · Primary completion 2027-12-01
non-weight indication: cognition, alzheimers
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer SurvivorsNCT07257484 · Recruiting · Phase 4 · 30 participants · Primary completion 2027-12-03 · BMI 27 or higher
non-weight indication: cancer
Feasibility of Semaglutide in Advanced Lung DiseaseNCT05746039 · Recruiting · Phase 1, Phase 2 · 8 participants · Primary completion 2027-12-28 · BMI 30 or higher
non-weight indication: cardiovascular
Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart FailureNCT06423599 · Recruiting · Phase 2, Phase 3 · 100 participants · Primary completion 2027-12-30 · BMI 30 or higher
non-weight indication: cardiovascular
Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial FibrillationNCT07382024 · Not yet recruiting · NA · 200 participants · Primary completion 2027-12-31 · BMI 27 or higher
non-weight indication: cardiovascular
Tirzepatide in the Treatment of Endometrial CancerNCT07605247 · Not yet recruiting · Phase 2 · 30 participants · Primary completion 2028-01 · BMI 27 or higher
non-weight indication: cancer
Combination of Biologic and Anti-obesity Therapies in Psoriatic ArthritisNCT07443956 · Recruiting · NA · 45 participants · Primary completion 2028-02 · BMI 27 or higher
non-weight indication: rheumatologic
Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and ReinitiationNCT07387796 · Recruiting · NA · 40 participants · Primary completion 2028-02
non-weight indication: addiction
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary SyndromeNCT05819853 · Recruiting · Phase 3 · 80 participants · Primary completion 2028-02-01 · BMI 95 or higher
non-weight indication: endocrine, other_emerging
Multi-Site Trial of Tirzepatide for Smoking CessationNCT07602699 · Recruiting · Phase 2 · 300 participants · Primary completion 2028-03
non-weight indication: addiction
Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA TrialNCT07676331 · Not yet recruiting · Phase 2 · 168 participants · Primary completion 2028-03-01
non-weight indication: cancer
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471 · Recruiting · Phase 3 · 800 participants · Primary completion 2028-04
non-weight indication: osteoarthritis
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086 · Recruiting · Phase 3 · 350 participants · Primary completion 2028-04 · BMI 27 or higher
non-weight indication: rheumatologic
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT TrialNCT07202247 · Recruiting · Phase 2 · 60 participants · Primary completion 2028-04-09 · BMI 30 or higher
non-weight indication: cardiovascular, cancer
Moving Beyond Inflammation as a Therapeutic Target for Crohn's DiseaseNCT06976853 · Recruiting · Phase 2 · 60 participants · Primary completion 2028-05
non-weight indication: inflammation, rheumatologic
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)NCT06857942 · Recruiting · Phase 4 · 200 participants · Primary completion 2028-05
non-weight indication: rheumatologic
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099 · Recruiting · Phase 3 · 290 participants · Primary completion 2028-05 · BMI 27 or higher
non-weight indication: rheumatologic
A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney DiseaseNCT07239570 · Recruiting · Phase 4 · 125 participants · Primary completion 2028-06
non-weight indication: kidney
Therapeutic Strategies for Microvascular Dysfunction in Type 1 DiabetesNCT05478707 · Recruiting · Phase 2 · 47 participants · Primary completion 2028-06-30
population of special interest (non-obese / healthy / non-diabetic)
Tirzepatide in the Treatment of Cannabis Use DisorderNCT07671248 · Not yet recruiting · Phase 3 · 15 participants · Primary completion 2028-07-31 · BMI 22 or higher
non-weight indication: addiction
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use DisorderNCT06939088 · Recruiting · Phase 2 · 108 participants · Primary completion 2028-08-01
non-weight indication: addiction, psychiatric
GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPDNCT07747805 · Not yet recruiting · Phase 2 · 30 participants · Primary completion 2028-08-15 · BMI 27 or higher
non-weight indication: muscle, other_emerging
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)NCT07718126 · Not yet recruiting · Phase 2, Phase 3 · 60 participants · Primary completion 2028-08-31 · BMI 24 or higher
non-weight indication: liver
A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or ObeseNCT07326111 · Recruiting · Phase 4 · 198 participants · Primary completion 2028-12 · BMI 27 or higher
non-weight indication: endocrine, other_emerging
Waiting on Atrial Fibrillation Intervention Therapy (WAIT) StudyNCT07275697 · Recruiting · Phase 4 · 200 participants · Primary completion 2028-12-30 · BMI 30 or higher
non-weight indication: cardiovascular, mortality
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · Active not recruiting · Phase 3 · 10000 participants · Primary completion 2029-02
non-weight indication: cardiovascular, kidney
Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial CancerNCT07078838 · Not yet recruiting · Phase 2 · 40 participants · Primary completion 2029-03
non-weight indication: cancer
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)NCT07218354 · Recruiting · Phase 3 · 622 participants · Primary completion 2029-03-31
non-weight indication: addiction
Incretin Therapies in Obesity-related HFpEFNCT07554638 · Recruiting · Phase 4 · 50 participants · Primary completion 2029-04 · BMI 30 or higher
non-weight indication: cardiovascular
Semaglutide PrIor to CathEeter Ablation in Patients With Atrial FibrillationNCT07389941 · Not yet recruiting · Phase 4 · 240 participants · Primary completion 2029-04
non-weight indication: cardiovascular
Liraglutide Treatment in Obese Infertile PCOS WomenNCT06742710 · Recruiting · Phase 4 · 890 participants · Primary completion 2029-05-30
non-weight indication: endocrine, other_emerging
Fibrosis Lessens After Metabolic SurgeryNCT06374875 · Recruiting · Phase 4 · 120 participants · Primary completion 2029-05-31 · BMI 35 or higher
non-weight indication: liver, addiction
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's DiseaseNCT07651319 · Recruiting · Phase 1, Phase 2 · 30 participants · Primary completion 2029-06
non-weight indication: inflammation, dementia, alzheimers
Glucagon-Like Peptide-1 Receptor Agonist in ADPKDNCT06582875 · Recruiting · Phase 2 · 126 participants · Primary completion 2029-06-30
non-weight indication: kidney, other_emerging
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial CancerNCT07781150 · Not yet recruiting · Phase 2 · 128 participants · Primary completion 2029-06-30 · BMI 24 or higher
non-weight indication: cancer
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579 · Not yet recruiting · Phase 3 · 2001 participants · Primary completion 2029-08
non-weight indication: cardiovascular
Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEFNCT07630454 · Not yet recruiting · Phase 4 · 602 participants · Primary completion 2029-08-01 · BMI 28 or higher
non-weight indication: cardiovascular
Tirzepatide Weight Loss for MRD+ Early Breast CancerNCT06517212 · Recruiting · Phase 2 · 48 participants · Primary completion 2029-08-31 · BMI 27 or higher
non-weight indication: cancer, mortality
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIVNCT07221214 · Recruiting · Phase 2 · 200 participants · Primary completion 2029-10-31 · BMI 23 or higher
non-weight indication: cardiovascular, addiction, other_emerging
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol SecretionNCT07361874 · Recruiting · NA · 75 participants · Primary completion 2030-05-31 · BMI 27 or higher
non-weight indication: kidney, endocrine
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 · Recruiting · Phase 3 · 4500 participants · Primary completion 2030-08
population of special interest (non-obese / healthy / non-diabetic)
Improved Treatment and Monitoring of Alzheimer's DiseaseNCT07135245 · Not yet recruiting · Phase 2 · 180 participants · Primary completion 2030-09-30
non-weight indication: cognition, alzheimers
Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase InhibitorsNCT07769047 · Not yet recruiting · Phase 4 · 50 participants · Primary completion 2031-07-30 · BMI 30 or higher
non-weight indication: cardiovascular, cancer
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)NCT07241390 · Recruiting · Phase 3 · 7140 participants · Primary completion 2031-08
non-weight indication: cardiovascular, kidney

02Changes

Recent registry changes

No changes recorded.